Phase III
The experimental drug, if approved, will compete with GlaxoSmithKline’s Benlysta, which is the only new drug approved for lupus in the last 60 years.
ACR Annual Meeting: Janssen’s Tremfya Nails Primary Endpoints in 24-Week Psoriatic Arthritis Studies
Both DISCOVER 1 and DISCOVER 2 are evaluating Tremfya in adults with active psoriatic arthritis.
It was a busy week for clinical trial updates for the first week of November. Here’s a look.
AR101 is an investigational, peanut-derived, biologic drug candidate for oral immunotherapy in patients with peanut allergy. It delivers a daily dose of peanut protein with a consistent protein profile.
The trial demonstrated that patients receiving esaxerenone has a significantly higher Urine Albumin-to-Creatinine Ratio (UACR) of 22.1% compared to 4.0% on placebo.
Esperion announced that pooled analyses from four Phase 3 clinical trials of bempedoic acid will be presented at the American Heart Association Scientific Sessions in Philadelphia on Sunday, November 17, 2019.
It was the first randomized, controlled trial comparing Toujeo to Gla-100 in this patient population.
On the same day Novartis announced that its Cosentyx didn’t prove itself superior to AbbVie’s Humira in psoriatic arthritis, AbbVie announced that its Rinvoq met the primary endpoint in active psoriatic arthritis in its SELECT-PsA 2 Phase III trial.
Novartis is careful to note that Cosentyx showed “numerically higher results versus Humira,” and that there are some statistically significant advantages of the drug over Humira.
ObsEva SA announced that the U.S. Food and Drug Administration has allowed the Company to begin enrolling patients in IMPLANT 3, the U.S pivotal Phase 3 clinical trial of nolasiban in women undergoing embryo transfer following in-vitro fertilization.
PRESS RELEASES